Thermo Fisher Scientific is launching a new test it says can help doctors avoid the “trial-and-error” approach typically used to dose patients with a common antirejection drug after organ transplant surgery.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Thermo Fisher Scientific is launching a new test it says can help doctors avoid the “trial-and-error” approach typically used to dose patients with a common antirejection drug after organ transplant surgery.